0000000000542898

AUTHOR

Cihan Yurdaydin

showing 2 related works from this author

From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005).

2006

Hepatitis B virus infection, which was for over a decade put aside by the rising star of hepatitis C, has seen over the last years a resurgence of interest. This stemmed from a better knowledge of the virus itself, from the availability of new drugs and combinations, and from the realization that far from being eradicated by mass immunization programs HBV is still on a worldwide basis the major cause of cirrhosis and hepatocellular carcinoma, alone or in combinations with other viruses, alcohol andmetabolic cofactors. This prompted the EASL Scientific Committee to organize a Monothematic Conference on HBV. Experts from Europe, USA, Canada, Australia, the Far East and other parts of the worl…

Hepatitis B virusmedicine.medical_specialtyHepatitis B virusHepatologybusiness.industryIstanbul turkeyhepatitis B viruHepatitis Chepatocellular carcinomamedicine.disease_causemedicine.diseaseHepatitis BVirologyHepatitis B AntigensMass immunizationChronic hepatitischronic hepatitiFamily medicinemedicineHumansViremiabusinesscirrhosiJournal of hepatology
researchProduct

The case for simplifying and using absolute targets for viral hepatitis elimination goals

2021

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes …

ddc:616Carcinoma HepatocellularHepatologyHepatitis Viral Humanbusiness.industryLiver Neoplasmsddc:616.07medicine.diseaseWorld Health OrganizationVirologydigestive system diseasesGoalInfectious DiseasesAbsolute (philosophy)SDG 3 - Good Health and Well-beingVirologymedicineHumansViral hepatitisbusinessGoalsHuman
researchProduct